Eli Lilly and Company: Dermatitis, Atopic trials

The registry lists 30 Dermatitis, Atopic studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 25 have results posted.

Phase 1 3Phase 2 5Phase 3 21Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling by invitationNCT05735483Phase 3
• Lebrikizumab Pen Ease of Use in Participants With Atopic DermatitisCompletedNCT06444165Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT06280716Phase 3Results posted
• A Study of LY3872386 in Healthy Participants and Participants With Atopic DermatitisTerminatedNCT06119529Phase 1Results posted
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic DermatitisTerminatedNCT05911841Phase 2Results posted
• A Study of LY3844583 in Healthy Participants and Participants With Atopic DermatitisTerminatedNCT05486208Phase 1Results posted
• A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of ColorCompletedNCT05372419Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabCompletedNCT05369403Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04760314Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)CompletedNCT04626297Phase 3Results posted
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)CompletedNCT04392154Phase 3Results posted
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04250350Phase 3Results posted
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.CompletedNCT04250337Phase 3Results posted
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic DermatitisCompletedNCT04178967Phase 3Results posted
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)CompletedNCT04146363Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisCompletedNCT03952559Phase 3Results posted
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic DermatitisTerminatedNCT03831191Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisCompletedNCT03733301Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03559270Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT03443024Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03435081Phase 3Results posted
• A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically AdvisableCompletedNCT03428100Phase 3Results posted
• A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisCompletedNCT03334435Phase 3Results posted
• Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334422Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334396Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02576938Phase 2Results posted
• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenCompletedNCT07006792Phase 4
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT05559359Phase 3
• A Study of LY3454738 in Healthy Participants and Participants With Atopic DermatitisCompletedNCT03750643Phase 1
• A Safety and Efficacy of DRM02 in Subjects With Atopic DermatitisCompletedNCT01993420Phase 2